Literature DB >> 19029217

Reformulating the hazard ratio to enhance communication with clinical investigators.

Marc Buyse.   

Abstract

Mesh：

Year:  2008        PMID： 19029217     DOI： 10.1177/1740774508098328

Source DB:  PubMed          Journal:  Clin Trials        ISSN： 1740-7745            Impact factor:   2.486


× No keyword cloud information.
  8 in total

1.  Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.

Authors:  Stefan Michiels; Richard F Potthoff; Stephen L George
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

2.  Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit.

Authors:  Julien Péron; Alexandre Lambert; Stephane Munier; Brice Ozenne; Joris Giai; Pascal Roy; Stéphane Dalle; Abigirl Machingura; Delphine Maucort-Boulch; Marc Buyse
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

3.  The Predictive Individual Effect for Survival Data.

Authors:  Beat Neuenschwander; Satrajit Roychoudhury; Simon Wandel; Kannan Natarajan; Emmanuel Zuber
Journal:  Ther Innov Regul Sci       Date:  2022-03-16       Impact factor: 1.778

4.  Restricted survival benefit with right-censored data.

Authors:  Shixiao Zhang; Michael L LeBlanc; Ying-Qi Zhao
Journal:  Biom J       Date:  2021-12-30       Impact factor: 1.715

5.  Potential misinterpretation of treatment effects due to use of odds ratios and logistic regression in randomized controlled trials.

Authors:  Mirjam J Knol; Ruben G Duijnhoven; Diederick E Grobbee; Karel G M Moons; Rolf H H Groenwold
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

6.  Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer.

Authors:  J Péron; P Roy; K Ding; W R Parulekar; L Roche; M Buyse
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

7.  An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.

Authors:  Julien Péron; Pascal Roy; Thierry Conroy; Françoise Desseigne; Marc Ychou; Sophie Gourgou-Bourgade; Trevor Stanbury; Laurent Roche; Brice Ozenne; Marc Buyse
Journal:  Oncotarget       Date:  2016-12-13

8.  Evaluating case management as a complex intervention: Lessons for the future.

Authors:  Anne-Sophie Lambert; Catherine Legrand; Sophie Cès; Thérèse Van Durme; Jean Macq
Journal:  PLoS One       Date:  2019-10-31       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.